A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

Status:
Withdrawn

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

To evaluate the antitumor activity following treatment with IPI-504 in patients with breast cancer.

Phase 1/Phase 2

MedImmune LLC